Press Releases

09.15.2016

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

09.14.2016

FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX® (varenicline)

09.13.2016

Pfizer Launches New “Moodivator” App to Help Support, Encourage and Motivate People with Depression

09.12.2016

Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic peptides

09.08.2016

AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics

09.07.2016

Pfizer Appoints Chief Scientific Officer for Neuroscience Research

09.06.2016

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Morgan Stanley Global Healthcare Conference

08.31.2016

XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer

08.23.2016

Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca

08.23.2016

Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016

08.19.2016

FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain

08.08.2016

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease